Zacks Investment Research upgraded shares of Quotient Limited (NASDAQ:QTNT) from a sell rating to a hold rating in a research note published on Tuesday morning.
According to Zacks, “Quotient Limited is a commercial-stage transfusion diagnostics company. It is focused on supplying blood-grouping consumables and developing MosaiQ, a fully automated platform for use in donor centers and patient-testing sites. Quotient Limited is headquartered in Edinburgh, Scotland and Newton, Pennsylvania. “
Other equities research analysts have also recently issued reports about the company. ValuEngine upgraded Quotient Limited from a strong sell rating to a sell rating in a research note on Friday, June 30th. BTIG Research reiterated a buy rating and set a $12.00 price target on shares of Quotient Limited in a research report on Thursday, August 31st.
Quotient Limited (NASDAQ:QTNT) last issued its quarterly earnings data on Monday, August 7th. The company reported ($0.55) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.55). Quotient Limited had a negative return on equity of 13,050.41% and a negative net margin of 381.66%. The company had revenue of $6.83 million for the quarter, compared to the consensus estimate of $5.70 million.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/2958123/quotient-limited-qtnt-upgraded-at-zacks-investment-research.html.
In other Quotient Limited news, insider D J. Paul E. Cowan sold 9,420 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $6.11, for a total value of $57,556.20. Following the sale, the insider now directly owns 26,666 shares of the company’s stock, valued at $162,929.26. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider D J. Paul E. Cowan sold 45,540 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $3.52, for a total value of $160,300.80. Following the completion of the sale, the insider now directly owns 26,666 shares in the company, valued at $93,864.32. The disclosure for this sale can be found here. Over the last three months, insiders sold 365,612 shares of company stock worth $1,884,079. 29.00% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the business. New York State Common Retirement Fund acquired a new stake in shares of Quotient Limited in the second quarter worth approximately $101,000. Goldman Sachs Group Inc. acquired a new stake in shares of Quotient Limited in the second quarter worth approximately $104,000. Nationwide Fund Advisors acquired a new stake in shares of Quotient Limited in the second quarter worth approximately $111,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Quotient Limited in the second quarter worth approximately $177,000. Finally, Rhumbline Advisers acquired a new stake in shares of Quotient Limited in the second quarter worth approximately $201,000. 57.71% of the stock is currently owned by institutional investors.
Quotient Limited Company Profile
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Quotient Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Limited and related companies with MarketBeat.com's FREE daily email newsletter.